Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2023 / N 2

Новые вакцины против туберкулеза
П.Н. Асташкевич, Л.Я. Французевич, Т.Н. Краснова

Список литературы

1. Gopalaswamy R, Subbian S. An update on tuberculosis vaccines. Methods in Molecular Biology (Clifton, N.J.) 2022;2410:387-409.
2. Bagcchi S. WHO’s global tuberculosis report 2022. The Lancet. Microbe 2023 Jan;4(1):e20.
3. World Health Organization. Global tuberculosis programme. Available from: https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy# Accessed 2023 Oct 05.
4. Li J, Zhao A, Tang J, Wang G, Shi Y, Zhan L, Qin C. Tuberculosis vaccine development: from classic to clinical candidates. European Journal of Clinical Microbiology & Infectious Diseases 2020 Aug;39(8):1405-25.
5. Scriba TJ, Coussens AK, Fletcher HA. Human immunology of tuberculosis. Jacobs WR Jr, McShane H, Mizrahi V, Orme IM, editors. Microbiology Spectrum 2016 Aug;4(4). doi: 10.1128/microbiolspec.TBTB2-0016-2016
6. Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: host defense vs pathogen evasion. Cellular & Molecular Immunology 2017 Dec;14(12):963-75.
7. de Martino M, Lodi L, Galli L, Chiappini E. Immune response to Mycobacterium tuberculosis: a narrative review. Frontiers in Pediatrics 2019 Aug;7:350.
8. Sia JK, Rengarajan J. Immunology of Mycobacterium tuber­culosis infections. Microbiology Spectrum 2019 Jul;7(4):10.1128/microbiolspec.GPP3-0022-2018.
9. Fatima S, Kumari A, Das G, Dwivedi VP. Tuberculosis vaccine: a journey from BCG to present. Life Sciences 2020 Jul;252:117594.
10. Romano M, Squeglia F, Kramarska E, Barra G, Choi HG, Kim HJ, Ruggiero A, Berisio R. A structural view at vaccine development against M. tuberculosis. Cells 2023 Jan;12(2):317.
11. Martin C, Aguilo N, Marinova D, Gonzalo-Asensio J. Update on TB vaccine pipeline. Applied Sciences 2020 Apr;10(7):2632.
12. Brazier B, McShane H. Towards new TB vaccines. Seminars in Immunopathology 2020 Jun;42(3):315-31.
13. De Castro MJ, Pardo-Seco J, Martinón-Torres F. Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis. Clinical Infectious Diseases 2015 Jun;60(11):1611-9.
14. Walk J, de Bree LCJ, Graumans W, Stoter R, van Gemert GJ, van de Vegte-Bolmer M, Teelen K, Hermsen CC, Arts RJW, Behet MC, Keramati F, Moorlag SJCFM, Yang ASP, van Crevel R, Aaby P, de Mast Q, van der Ven AJAM, Stabell Benn C, Netea MG, Sauerwein RW. Outcomes of controlled human malaria infection after BCG vaccination. Nature Communiations 2019 Feb;10(1):874.
15. Netea MG, Joosten LAB, Latz E, Mills KHG, Natoli G, Stunnenberg HG, O’Neill LAJ, Xavier RJ. Trained immunity: a program of innate immune memory in health and disease. Science (New York, N.Y.) 2016 Apr;352(6284):aaf1098.
16. Darrah PA, Zeppa JJ, Maiello P, Hackney JA, Wadsworth MH 2nd, Hughes TK, Pokkali S, Swanson PA 2nd, Grant NL, Rodgers MA, Kamath M, Causgrove CM, Laddy DJ, Bonavia A, Casimiro D, Lin PL, Klein E, White AG, Scanga CA, Shalek AK, Roederer M, Flynn JL, Seder RA. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature 2020 Jan;577(7788):95-102.
17. Dijkman K, Sombroek CC, Vervenne RAW, Hofman SO, Boot C, Remarque EJ, Kocken CHM, Ottenhoff THM, Kon­dova I, Khayum MA, Haanstra KG, Vierboom MPM, Verreck FAW. Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques. Nature Medicine 2019 Feb;25(2):255-62.
18. Hatherill M, Tait D, McShane H. Clinical testing of tuberculosis vaccine candidates. Microbiology Spectrum 2016 Oct;4(5). doi: 10.1128/microbiolspec.TBTB2-0015-2016.
19. Kaufmann SHE. Vaccination against tuberculosis: revamping BCG by molecular genetics guided by immunology. Frontiers in Immunology 2020 Feb;11:316.
20. Sable SB, Posey JE, Scriba TJ. Tuberculosis vaccine development: progress in clinical evaluation. Clinical Microbiology Reviews 2019 Oct;33(1):e00100-19.
21. Evans TG, Schrager L, Thole J. Status of vaccine research and development of vaccines for tuberculosis. Vaccine 2016 Jun;34(26):2911-4.
22. TuBerculosis Vaccine Initiative. Pipeline of vaccines. Available from: https://www.tbvi.eu/what-we-do/pipeline-of-vaccines/ Accessed 2023 Oct 05.
23. Bouzeyen R, Javid B. Therapeutic vaccines for tuberculosis: an overview. Frontiers in Immunology 2022 Jun;13:878471.
24. Nieuwenhuizen NE, Kulkarni PS, Shaligram U, Cotton MF, Rentsch CA, Eisele B, Grode L, Kaufmann SHE. The recombinant bacille Calmette–Guérin vaccine VPM1002: ready for clinical efficacy testing. Frontiers in Immunology 2017 Sep;8:1147.
25. Cotton MF, Madhi SA, Luabeya AK, Tameris M, Hesseling AC, Shenje J, Schoeman E, Hatherill M, Desai S, Kapse D, Brückner S, Koen A, Jose L, Moultrie A, Bhikha S, Walzl G, Gutschmidt A, Kotze LA, Allies DL, Loxton AG, Shaligram U, Abraham M, Johnstone H, Grode L, Kaufmann SHE, Kulkarni PS. Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. The Lancet. Infectious Diseases 2022 Oct;22(10):1472-83.
26. Gonzalo-Asensio J, Marinova D, Martin C, Aguilo N. MTBVAC: attenuating the human pathogen of tuberculosis (TB) toward a promising vaccine against the TB epidemic. Frontiers in Immunology 2017 Dec;8:1803.
27. Kaufmann SHE. Tuberculosis vaccines: time to think about the next generation. Seminars in Immunology 2013 Apr;25(2):172-81.
28. Vilaplana C, Montané E, Pinto S, Barriocanal AM, Domenech G, Torres F, Cardona PJ, Costa J. Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI®. Vaccine 2010 Jan;28(4):1106-16.
29. Nell AS, D’Lom E, Bouic P, Sabaté M, Bosser R, Picas J, Amat M, Churchyard G, Cardona PJ. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One 2014 Feb;9(2):e89612.
30. Munseri P, Said J, Amour M, Magohe A, Matee M, Rees CA, Mackenzie T, Tvaroha S, Bailey-Kellogg C, Maro I, Wieland-Alter W, Adams LV, Horsburgh CR, Nakamura K, Arbeit RD, Pallangyo K, von Reyn CF. DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: a randomized controlled, double-blind phase 2b trial. Vaccine 2020;38(46):7239-45.
31. Sharma P, Misra RS, Kar HK, Mukherjee A, Poricha D, Kaur H, Mukherjee R, Rani R. Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multibacillary leprosy: a report on hospital based immunotherapeutic clinical trials with a follow-up of 1–7 years after treatment. Leprosy Review 2000 Jun;71(2):179-92.
32. Saqib M, Khatri R, Singh B, Gupta A, Kumar A, Bhaskar S. Mycobacterium indicus pranii as a booster vaccine enhances BCG induced immunity and confers higher protection in animal models of tuberculosis. Tuberculosis 2016 Dec;101:164-73.
33. McClean S. Prospects for subunit vaccines: technology advances resulting in efficacious antigens requires matching advances in early clinical trial investment. Human Vaccines & Immunotherapeutics 2016 Dec;12(12):3103-6.
34. Junqueira-Kipnis AP, Marques Neto LM, Kipnis A. Role of fused Mycobacterium tuberculosis immunogens and adjuvants in modern tuberculosis vaccines. Frontiers in Immunology 2014 Apr;5:188.
35. Ahsan MJ. Recent advances in the development of vaccines for tuberculosis. Therapeutic Advances in Vaccines 2015 May;3(3):66-75.
36. Luabeya AKK, Kagina BMN, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, Kromann I, Hatherill M, Mahomed H, Hanekom WA, Andersen P, Scriba TJ, Schoeman E, Krohn C, Day CL, Africa H, Makhethe L, Smit E, Brown Y, Suliman S, Hughes EJ, Bang P, Snowden MA, McClain B, Hussey GD. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine 2015 Aug;33(33):4130-40.
37. Jenum S, Tonby K, Rueegg CS, Rühwald M, Kristiansen MP, Bang P, Olsen IC, Sellæg K, Røstad K, Mustafa T, Taskén K, Kvale D, Mortensen R, Dyrhol-Riise AM. A phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients. Nature Communications 2021 Nov;12(1):6774.
38. Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, Vergara J, Mabwe S, Bilek N, Geldenhuys H, Luabeya AK, Ellis R, Ginsberg AM, Hanekom WA, Reed SG, Coler RN, Scriba TJ, Hatherill M; TBVPX-114 study team. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. The Lancet. Respiratory Medicine 2018 Apr;6(4):287-98.
39. Day TA, Penn-Nicholson A, Luabeya AKK, Fiore-Gartland A, Du Plessis N, Loxton AG, Vergara J, Rolf TA, Reid TD, Toefy A, Shenje J, Geldenhuys H, Tameris M, Mabwe S, Bilek N, Bekker LG, Diacon A, Walzl G, Ashman J, Frevol A, Sagawa ZK, Lindestam Arlehamn C, Sette A, Reed SG, Coler RN, Scriba TJ, Hatherill M; TBVPX-203 study team. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet. Respiratory Medicine 2021 Apr;9(4):373-86.
40. Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, Scriba TJ, Akite EJ, Ayles HM, Bollaerts A, Demoitié MA, Diacon A, Evans TG, Gillard P, Hellström E, Innes JC, Lempicki M, Malahleha M, Martinson N, Mesia Vela D, Muyoyeta M, Nduba V, Pascal TG, Tameris M, Thienemann F, Wilkinson RJ, Roman F. Final analysis of a trial of M72/AS01 E vaccine to prevent tuberculosis. The New England Journal of Medicine 2019 Dec;381(25):2429-39.
41. Lu JB, Chen BW, Wang GZ, Fu LL, Shen XB, Su C, Du WX, Yang L, Xu M. Recombinant tuberculosis vaccine AEC/BC02 induces antigen-specific cellular responses in mice and protects guinea pigs in a model of latent infection. Journal of Microbiology, Immunology and Infection 2015 Dec;48(6):597-603.
42. Lu J, Guo X, Wang C, Du W, Shen X, Su C, Wu Y, Xu M. Therapeutic effect of subunit vaccine AEC/BC02 on Mycobacterium tuberculosis post-chemotherapy relapse using a latent infection murine model. Vaccines 2022 May;10(5):825.
43. Tkachuk AP, Bykonia EN, Popova LI, Kleymenov DA, Semashko MA, Chulanov VP, Fitilev SB, Maksimov SL, Smo­lyarchuk EA, Manuylov VA, Vasina DV, Gushchin VA, Gintsburg AL. Safety and immunogenicity of the GamTBvac, the recombinant subunit tuberculosis vaccine candidate: a phase II, multi-center, double-blind, randomized, placebo-controlled study. Vaccines 2020 Nov;8(4):652.
44. Humphreys IR, Sebastian S. Novel viral vectors in infectious diseases. Immunology 2018 Jan;153(1):1-9.
45. Stylianou E, Griffiths KL, Poyntz HC, Harrington-Kandt R, Dicks MD, Stockdale L, Betts G, McShane H. Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. Vaccine 2015 Nov;33(48):6800-8.
46. Wilkie M, Satti I, Minhinnick A, Harris S, Riste M, Ramon RL, Sheehan S, Thomas ZM, Wright D, Stockdale L, Hamidi A, O’Shea MK, Dwivedi K, Behrens HM, Davenne T, Morton J, Vermaak S, Lawrie A, Moss P, McShane H. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults. Vaccine 2020 Jan;38(4):779-89.
47. Smaill F, Xing Z. Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future? Expert Review of Vaccines 2014 Aug;13(8):927-30.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]